NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET FORECAST 2017-2025
KEY FINDINGS
The North America botanical and plant derivative drug market was valued at $5222 million in 2016. The market is predicted to expand at a CAGR of 2.40%, generating $6600 million by the end of the forecast period of 2017-2025.
MARKET INSIGHTS
Several noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Administration (FDA) for deployment as prescription drugs. The increasing approval by FDA for botanical drugs and their escalating usage in the regions are presenting the market with potential growth opportunities.
COMPETITIVE INSIGHTS
Some of the major players in the market are Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, Novartis International Ag, Tasly Pharmaceuticals Inc, GlaxoSmithKline, Abbott, Lupin Ltd, Bayer Healthcare Llc, Medigene, and Pfizer.
The North America botanical and plant derivative drug market was valued at $5222 million in 2016. The market is predicted to expand at a CAGR of 2.40%, generating $6600 million by the end of the forecast period of 2017-2025.
MARKET INSIGHTS
Several noted vendors in North America are increasingly promoting the deployment of botanical drugs and products as key dietary supplements. However, only a few products have been approved by the United States Food and Drug Administration (FDA) for deployment as prescription drugs. The increasing approval by FDA for botanical drugs and their escalating usage in the regions are presenting the market with potential growth opportunities.
COMPETITIVE INSIGHTS
Some of the major players in the market are Eli Lilly And Company, Glenmark Pharmaceuticals Ltd, Novartis International Ag, Tasly Pharmaceuticals Inc, GlaxoSmithKline, Abbott, Lupin Ltd, Bayer Healthcare Llc, Medigene, and Pfizer.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ON THE BASIS OF TYPES, GLYCOSIDES ARE FAST EXPANDING
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. THE MARKET FOR HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2017-2025
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.3. BIONOVA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVE
9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVE
9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVE
9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.12. PFIZER
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.14.1. OVERVIEW
9.14.2. PRODUCTION PORTFOLIO
9.14.3. STRATEGIC INITIATIVE
9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
9.15.1. OVERVIEW
9.15.2. PRODUCTION PORTFOLIO
9.15.3. SCOT ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. ON THE BASIS OF TYPES, GLYCOSIDES ARE FAST EXPANDING
3.2.2. ONCOLOGY HOLDS THE LARGEST MARKET SHARE IN TERMS OF THERAPEUTIC APPLICATION
3.2.3. THE MARKET FOR HERBAL/TRADITIONAL TOPICAL ANALGESICS PRODUCT IS GROWING RAPIDLY
4. MARKET DYNAMICS
4.1. DRIVERS
4.1.1. GROWING APPLICATIONS IN DISEASES
4.1.2. GROWING FDA APPROVALS
4.1.3. TECHNOLOGICAL DEVELOPMENT IN THE MANUFACTURING PROCESS
4.1.4. RISING DEMAND FOR TRADITIONAL MEDICINES
4.1.5. GROWING FOCUS TOWARDS NATURAL SOURCE MEDICINES
4.2. RESTRAINTS
4.2.1. STRINGENT REGULATIONS REGARDING THE USE AND APPROVAL OF BOTANICAL DRUGS
4.2.2. LIMITED ADOPTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
4.3. OPPORTUNITIES
4.3.1. RISING FDA APPROVALS FOR BOTANICAL DRUGS
4.3.2. ESCALATING USAGE OF BOTANICAL DRUGS
4.4. CHALLENGES
4.4.1. PRESENCE OF SUBSTITUTES FOR BOTANICAL & PLANT DERIVATIVE DRUG
4.4.2. TOXICITY RELATED ISSUES AND SAFETY CONCERNS
5. MARKET SEGMENTATION
5.1. MARKET BY TYPES 2017-2025
5.1.1. TERPENES
5.1.2. STEROIDS
5.1.3. GLYCOSIDES
5.1.4. PHENOLS
5.1.5. OTHER TYPES
5.2. MARKET BY THERAPEUTIC APPLICATIONS 2017-2025
5.2.1. ONCOLOGY
5.2.2. DERMATOLOGY
5.2.3. CNS DISORDERS
5.2.4. HORMONE DISEASES
5.2.5. OTHER THERAPEUTIC APPLICATIONS
5.3. MARKET BY PRODUCTS 2017-2025
5.3.1. HERBAL/TRADITIONAL TOPICAL ANALGESICS
5.3.2. HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES
5.3.3. HERBAL/TRADITIONAL DIGESTIVE REMEDIES
5.3.4. HERBAL/TRADITIONAL DERMATOLOGICAL
5.3.5. HERBAL/TRADITIONAL PEDIATRIC DIETARY SUPPLEMENTS
5.3.6. HERBAL/TRADITIONAL DIETARY SUPPLEMENTS
5.3.7. HERBAL/TRADITIONAL TONICS
6. KEY ANALYTICS
6.1. MANUFACTURING PROCESS
6.2. VALUE CHAIN ANALYSIS
6.3. LEGAL, POLICY AND REGULATORY FRAMEWORK
6.4. PORTER’S FIVE FORCES ANALYSIS
6.4.1. THREAT OF NEW ENTRANTS
6.4.2. THREATS OF SUBSTITUTE PRODUCT
6.4.3. BARGAINING POWER OF BUYER
6.4.4. BARGAINING POWER OF SUPPLIER
6.4.5. INTENSITY OF COMPETITIVE RIVALRY
6.5. KEY BUYING CRITERIA
7. GEOGRAPHIC ANALYSIS
7.1. NORTH AMERICA
7.1.1. UNITED STATES
7.1.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIES
8.1.1. MERGER & ACQUISITION
8.1.2. PARTNERSHIP & COLLABORATION
8.1.3. EXPANSION & INVESTMENT
8.2. MARKET SHARE ANALYSIS
8.3. KEY COMPANIES ANALYSIS
9. COMPANY PROFILE
9.1. ABBOTT LABORATORIES
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. STRATEGIC INITIATIVES
9.1.4. SCOT ANALYSIS
9.2. BAYER HEALTHCARE LLC
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.3. BIONOVA
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.4. BRISTOL-MYERS SQUIBB
9.4.1. OVERVIEW
9.4.2. STRATEGIC INITIATIVE
9.4.3. SCOT ANALYSIS
9.5. CURA PHARM
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.6. ELI LILLY AND COMPANY
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
9.6.3. SCOT ANALYSIS
9.7. GLAXOSMITHKLINE
9.7.1. OVERVIEW
9.7.2. PRODUCT PORTFOLIO
9.7.3. STRATEGIC INITIATIVES
9.7.4. SCOT ANALYSIS
9.8. GLENMARK PHARMACEUTICALS LTD.
9.8.1. OVERVIEW
9.8.2. PRODUCT PORTFOLIO
9.8.3. STRATEGIC INITIATIVE
9.8.4. SCOT ANALYSIS
9.9. LUPIN LTD
9.9.1. OVERVIEW
9.9.2. PRODUCT PORTFOLIO
9.9.3. STRATEGIC INITIATIVE
9.9.4. SCOT ANALYSIS
9.10. MEDIGENE
9.10.1. OVERVIEW
9.10.2. PRODUCT PORTFOLIO
9.10.3. STRATEGIC INITIATIVES
9.10.4. SCOT ANALYSIS
9.11. NOVARTIS INTERNATIONAL AG
9.11.1. OVERVIEW
9.11.2. PRODUCT PORTFOLIO
9.11.3. STRATEGIC INITIATIVES
9.11.4. SCOT ANALYSIS
9.12. PFIZER
9.12.1. OVERVIEW
9.12.2. PRODUCT PORTFOLIO
9.12.3. STRATEGIC INITIATIVE
9.12.4. SCOT ANALYSIS
9.13. PIRAMAL PHYTOCARE LTD.
9.13.1. OVERVIEW
9.13.2. PRODUCT PORTFOLIO
9.13.3. STRATEGIC INITIATIVE
9.13.4. SCOT ANALYSIS
9.14. RANBAXY LABORATORIES LTD (ACQUIRED BY SUN PHARMACEUTICALS LTD)
9.14.1. OVERVIEW
9.14.2. PRODUCTION PORTFOLIO
9.14.3. STRATEGIC INITIATIVE
9.14.4. SCOT ANALYSIS
9.15. TASLY PHARMACEUTICALS INC.
9.15.1. OVERVIEW
9.15.2. PRODUCTION PORTFOLIO
9.15.3. SCOT ANALYSIS
LIST OF TABLES
Table 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
Table 2 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
Table 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
Table 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Table 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
Table 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
Table 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Table 8 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
Table 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
Table 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
Table 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 13 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
Table 14 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
Table 15 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
Table 16 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
Table 17 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
Table 18 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 19 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 20 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
Table 21 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Table 22 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Table 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, 2017-2025 ($ MILLION)
Table 2 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET, BY TYPES 2017-2025 ($ MILLION)
Table 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES, 2017-2025 ($ MILLION)
Table 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Table 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES, BY GEOGRAPHY 2017-2025 ($ MILLION)
Table 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS, 2017-2025 ($ MILLION)
Table 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Table 8 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET BY THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY, 2017-2025 ($ MILLION)
Table 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY, 2017-2025 ($ MILLION)
Table 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS, 2017-2025 ($ MILLION)
Table 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Table 13 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET, BY PRODUCT 2017-2025 ($ MILLION)
Table 14 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS, 2017-2025 ($ MILLION)
Table 15 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES, 2017-2025 ($ MILLION)
Table 16 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES, 2017-2025 ($ MILLION)
Table 17 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS, 2017-2025 ($ MILLION)
Table 18 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 19 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS, 2017-2025 ($ MILLION)
Table 20 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS, 2017-2025 ($ MILLION)
Table 21 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Table 22 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
LIST OF FIGURES
Figure 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 2 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
Figure 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Figure 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
Figure 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Figure 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
Figure 8 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
Figure 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
Figure 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
Figure 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
Figure 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Figure 13 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
Figure 14 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
Figure 15 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
Figure 16 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
Figure 17 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 18 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 19 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
Figure 20 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
Figure 21 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 22 UNITED STATES BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 23 CANADA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 1 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 2 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN TERPENES 2017-2025 ($ MILLION)
Figure 3 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN STEROIDS 2017-2025 ($ MILLION)
Figure 4 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN GLYCOSIDES 2017-2025 ($ MILLION)
Figure 5 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN PHENOLS 2017-2025 ($ MILLION)
Figure 6 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHER TYPES 2017-2025 ($ MILLION)
Figure 7 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN ONCOLOGY 2017-2025 ($ MILLION)
Figure 8 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN DERMATOLOGY 2017-2025 ($ MILLION)
Figure 9 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN CNS DISORDERS 2017-2025 ($ MILLION)
Figure 10 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE 2017-2025 ($ MILLION)
Figure 11 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN HORMONE DISEASE, 2017-2025 ($ MILLION)
Figure 12 NORTH AMERICA BOTANICAL AND PLANT DERIVATIVE DRUG MARKET IN OTHERS THERAPEUTIC APPLICATIONS 2017-2025 ($ MILLION)
Figure 13 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TOPICAL ANALGESICS 2017-2025 ($ MILLION)
Figure 14 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL COUGH, COLD AND ALLERGY (HAY FEVER) REMEDIES 2017-2025 ($ MILLION)
Figure 15 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIGESTIVE REMEDIES 2017-2025 ($ MILLION)
Figure 16 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DERMATOLOGICALS 2017-2025 ($ MILLION)
Figure 17 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL PAEDIATRIC DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 18 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL DIETARY SUPPLEMENTS 2017-2025 ($ MILLION)
Figure 19 NORTH AMERICA BOTANICAL AND DERIVATIVE DRUG MARKET IN HERBAL/TRADITIONAL TONICS 2017-2025 ($ MILLION)
Figure 20 EVOLUTION OF BOTANICAL AND PLANT DERIVATIVE DRUGS
Figure 21 NORTH AMERICA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 22 UNITED STATES BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
Figure 23 CANADA BOTANICAL & PLANT DERIVATIVE DRUG MARKET 2017-2025 ($ MILLION)
